Health
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial
WILMINGTON, Del., September 29, 2025--Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/114c40f4a18b76b7a6cb3f91711dafcd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/dbrR6feT2uDRtrxp14nmAw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/114c40f4a18b76b7a6cb3f91711dafcd","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/IfVyoTdPWI7wq1BJE6fs4w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/114c40f4a18b76b7a6cb3f91711dafcd","width":1024,"height":512}},"lazy":false},{"type":"text","content":"Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s ENHERTU in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting","length":206,"tagName":"p","attribs":{}},{"type":"text","content":"Results from the DESTINY-Breast05 and DESTINY-Breast11 trials will be presented at ESMO 2025 in a Presidential Symposium","length":120,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Del., September 29, 2025--(BUSINESS WIRE)--Positive high-level results from a planned interim analysis of the DESTINY-Breast05 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) versus trastuzumab emtansine (T-DM1) in patients with HER2-positive early breast cancer with residual invasive disease in the breast or axillary lymph nodes after neoadjuvant treatment and a high-risk of disease recurrence. This is the second positive Phase III trial of ENHERTU in the HER2-positive early breast cancer setting following positive results from the DESTINY-Breast11 Phase III neoadjuvant trial earlier this year.","length":759,"tagName":"p"},{"type":"text","content":"Overall survival (OS) was not mature at the time of this planned interim analysis and will be assessed at a subsequent analysis.","length":128,"tagName":"p"},{"type":"text","content":"Currently, approximately half of patients with HER2-positive early breast cancer have residual disease following neoadjuvant treatment, putting them at an increase...